Cullen Capital Management LLC Sells 6,565,339 Shares of Kenvue Inc. $KVUE

Cullen Capital Management LLC decreased its position in Kenvue Inc. (NYSE:KVUE) by 72.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,484,940 shares of the company’s stock after selling 6,565,339 shares during the quarter. Cullen Capital Management LLC owned approximately 0.13% of Kenvue worth $52,010,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Truvestments Capital LLC bought a new stake in Kenvue in the 1st quarter worth about $37,000. Trust Co. of Vermont boosted its stake in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the last quarter. Ransom Advisory Ltd bought a new position in shares of Kenvue in the first quarter valued at approximately $56,000. First Pacific Financial purchased a new stake in shares of Kenvue during the second quarter valued at approximately $54,000. Finally, UMB Bank n.a. increased its position in shares of Kenvue by 22.3% during the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after acquiring an additional 521 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Rothschild & Co Redburn raised Kenvue from a “neutral” rating to a “buy” rating and cut their price objective for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Citigroup cut their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. Barclays raised their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. The Goldman Sachs Group dropped their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, October 2nd. Finally, Redburn Partners set a $22.00 price target on shares of Kenvue in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $17.32 on Monday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $33.18 billion, a PE ratio of 23.09 and a beta of 0.59. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The company has a 50-day moving average price of $16.20 and a two-hundred day moving average price of $19.06.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is currently 110.67%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.